Assertio Holdings

Update in progress

ASRT (NGM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Assertio Holdings, Inc. is a U.S. pharmaceutical company based in Lake Forest, Illinois. Its marketed products include INDOCIN for moderate to severe pain and inflammatory conditions; Sympazan for adjunctive treatment of seizures in Lennox-Gastaut syndrome in patients aged two and older; CAMBIA for migraine relief; SPRIX for short-term moderate to moderately severe pain; and ROLVEDON to reduce infection risk from febrile neutropenia. Formerly Assertio Therapeutics, it changed its name in 2020.

Company score

Sentiment: 0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.02; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.12; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive